Overview

The Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabidiol (CBD) Under Acute and Chronic Exposure Conditions

Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetic and pharmacodynamic effects of oral Cannabidiol (with or without low levels of THC), under acute and chronic dosing conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Johns Hopkins University
Treatments:
Epidiolex